A Post-mortem on the Failed Nektar-BMS Partnership at ESMO

The European Society for Medical Oncology (ESMO) conference is serving as a post-mortem on the trials that sunk the multi-billion-dollar partnership between Bristol-Myers Squibb and Nektar Therapeutics.